Prosiectau (339)
Cardiff University Schools involved in this Project
The South Wales and South West England Mental Health Platform Hub (01.04.2024 - 31.03.2029)
- Walters, James
To establish minimal residual disease as a surrogate for overall survival in acute myeloid leukemia (07.03.2024 - 06.03.2025)
- Thomas, Ian
The development of novel applications of INDUCE-seq (01.02.2024 - 31.03.2026)
- Reed, Simon
Towards new therapies for TED: translating scRNAseq insights into B cell infiltration of orbital fat and multi-faceted functions of fibroblasts into predictive biomarkers and novel drug targets (15.01.2024 - 14.07.2024)
- Hanna, Stephanie
TIPTOE Excess Treatment Costs (ETC) (10.01.2024 - 30.11.2025)
- Button, Kate
Targeting the early endosome as a therapeutic strategy in neurodegenerative diseases (01.01.2024 - 14.04.2027)
- Connor-Robson, Natalie
- Treg-sparing co-stimulation blockade: testing a novel immunosuppression
strategy in people with Type 1 diabetes (01.01.2024 - 31.12.2025)- Tatovic, Danijela
T1D-Plus: An adaptive trial platform for the study of combination therapies in new-onset T1D (01.12.2023 - 30.11.2026)
- Dayan, Colin
The impact of AD-associated risk variants in complement genes on neurodegeneration (01.10.2023 - 30.09.2026)
- Carpanini, Sarah
Tracking disease progression in early stage T1D using an automated version of the oral minimal model (01.10.2023 - 30.09.2026)
- Dayan, Colin
The sleep detectives: sleep stratification in young people at high risk of psychosis (04.09.2023 - 03.09.2026)
- van den Bree, Marianne
The Moondance Dementia Research Laboratory (01.09.2023 - 31.08.2028)
- Williams, Julie
The role of donor rerived cell free DNA (DD cfDNA) (11.07.2023 - 10.07.2028)
- Dayan, Colin
Trial Activity Attributions and costs in Clinical Trials Units (01.06.2023 - 30.11.2023)
- Denton, Rhys
The impact of a key molecular complex, (ALCAM), in the development of cancer and cancer metastasis (01.04.2023 - 31.03.2026)
- Jiang, Wen
The interaction between early chronic kidney disease-associated endogenous ligands of TLRs and adaptive immune cells and its impact on atherosclerosis. (01.03.2023 - 28.02.2026)
- Raby, Anne-Catherine
Targeting CD8 using “blocking anti CD8 antibodies” as a strategy to disable autoreactive CD8+ T-cells in Type 1 diabetes (01.01.2023 - 29.02.2024)
- Pearson, James
The contribution of maternally expressed imprinted genes to parental behaviour (01.12.2022 - 28.04.2026)
- Isles, Anthony
ThinkCancer!: A pragmatic randomised controlled phase III trial of a novel behavioural intervention for primary care teams to promote earlier cancer diagnosis with embedded process and economic evaluation (01.12.2022 - 30.11.2024)
- Carson-Stevens, Andrew
Translational Cell Therapy Placements in Advanced Therapies and Biologics for Cancer. (01.11.2022 - 30.09.2023)
- Evans, Mererid
- The impact of schizophrenia-associated copy number variants on cortical network dynamics
(24.10.2022 - 23.04.2027)- Hall, Jeremy
Talking Trials: Participatory approaches to creating community dialogue (01.10.2022 - 31.01.2024)
- Svobodova, Martina
Targeting complement to treat fatty liver disease (01.10.2022 - 30.09.2025)
- Zhou, You
Towards Cancer Patient empowerment for Optimal Use of Antithrombotic Therapy at the End of Life (01.10.2022 - 30.09.2027)
- Noble, Simon
T1D-Plus: a clinical trial platform for combined beta cell preservation therapy (01.09.2022 - 31.08.2026)
- Dayan, Colin